{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 5,
        "end": 13
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 16,
        "end": 24
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 112,
        "end": 138
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 141,
        "end": 146
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 158,
        "end": 165
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 171,
        "end": 175
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "23982599_5",
  "text": "Oral afatinib ( Gilotrif ) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer ( NSCLC ) who have tumours with EGFR exon 19 deletions or exon 21 ( L858R ) substitution mutations as detected by a US FDA-approved test ."
}
